Tasos Konidaris - Aug 13, 2025 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Executive Vice President & CFO
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Stock symbol
AMRX
Transactions as of
Aug 13, 2025
Transactions value $
-$4,663,070
Form type
4
Date filed
8/15/2025, 04:30 PM
Previous filing
Mar 7, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Konidaris Tasos Executive Vice President & CFO C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER /s/ Denis Butkovic, Attorney-in-Fact 2025-08-15 0001320982

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Sale -$1.49M -161K -25.95% $9.22 461K Aug 13, 2025 Direct F1
transaction AMRX Class A Common Stock Sale -$1.11M -119K -25.89% $9.30 341K Aug 14, 2025 Direct F2
transaction AMRX Class A Common Stock Sale -$2.07M -219K -64.21% $9.43 122K Aug 15, 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
F2 The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.34 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
F3 The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.